RP 1664 |
Katalog-Nr.GC92681
One-Click Copy Product Info
|
RP 1664 is an inhibitor of polo-like kinase 4 (Plk4; IC50 = 3 nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2980682-00-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
RP 1664 is an inhibitor of polo-like kinase 4 (Plk4; IC50 = 3 nM). It induces centriole depletion in hTERT RPE-1 retinal pigment cells (EC50 = 0.13 µM). RP 1664 induces cytotoxicity in MCF-7 breast cancer cells (EC50 = 0.051 µM). It reduces tumor volume in a CAL-148 breast cancer mouse xenograft model when administered at doses of 11 or 21 mg/kg twice per day.
| Cas No. | 2980682-00-4 | SDF | |
| Chemical Name | 5-cyclopropyl-N2-(2,6-difluoro-4-(methylsulfonyl)phenyl)-N2-methyl-6-(1-methyl-1H-imidazol-4-yl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine | ||
| Canonical SMILES | CC1=CC(NC2=C(C3CC3)C(C4=CN(C)C=N4)=NC(N(C(C(F)=CC(S(C)(=O)=O)=C5)=C5F)C)=N2)=NN1 | ||
| Formula | C23H24F2N8O2S | M.Wt | 514.555806 |
| Löslichkeit | Acetonitrile: Slightly soluble: 0.1-1 mg/ml; DMSO: Slightly soluble: 0.1-1 mg/ml | Storage | -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9434 mL | 9.7171 mL | 19.4342 mL |
| 5 mM | 388.7 μL | 1.9434 mL | 3.8868 mL |
| 10 mM | 194.3 μL | 971.7 μL | 1.9434 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)